EGFR and non-small cell lung carcinoma: Interestingly, first-line sensitivity to EGFR TKIs in NSCLC has been associated with pre-existent Akt activation that is suppressed by EGFR inhibition, while treatment with EGFR TKIs failed to block Akt signaling in tumor cells intrinsically resistant to these drugs28–31.